Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03039114
Title Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Incyte Corporation
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ITA | HUN | ESP | DNK | CZE


No variant requirements are available.